Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
March 30, 2022 11:32 AM 3 min read

Cannabis M&A Activity On Fire: But Is It What Was Expected? Experts Say, Look At Q1 Earnings

by Andrew Ward
Follow

Consolidation of the cannabis industry is inevitable as the market matures.

Heading into 2022, numerous forecasts predicted another flurry of M&A activity after an energized 2021. With nearly three months of the year complete, opinions are split on M&A activity so far.

M&A In 2022 Is On Fire

In one camp, sources say that M&A is right on track with forecasts calling for another year of consolidation.

Matt Hawkins, a managing partner at Entourage Effect Capital, said significant M&A deals appear on the single-state and national levels.

Hawkins cited various examples, including Cresco Labs Inc (OTC:CRLBF) recently announced plans to acquire Columbia Care Inc (OTC:CCHWF) for $2.1 billion. He also noted Harborside Inc (OTC:HBORF) deals to acquire Urbn Leaf and Loudpack to form StateHouse Holdings.

"It's evident that M&A is driving industry growth for the foreseeable future," Hawkins said.

Julie Herzog, a partner at Fortis Law Partners, agreed "in the sense that we're continuing to see major players focused on ensuring they remain number one through mergers and acquisitions."

She said smaller companies are trying to stand out as attractive acquisitions by becoming regional or product categories leaders.

Going back to October 2021, Herzog cites Canopy Growth Corp's (NASDAQ:CGC) $300 million purchase of Wana Brands, pending THC legalization in the US, as an example of things to come.

"I expect to continue to see many similarly structured deals and am encouraging my clients to begin preparing their companies for potential M&A now before federal legalization happens," Herzog said.

David Farris, VP of sales and marketing for Planet 13 Holdings Inc (OTC:PLNHF), sees specific states becoming attractive M&A targets.

"I definitely see emerging markets such as Florida as a major opportunity for cannabis industry growth," Farris.

Planet 13 announced plans to enter the state through a $55 million Harvest Health & Recreation subsidiary purchase in September 2021. In March 2022, the company announced the Jacksonville suburb of Orange Park as its first Florida dispensary location.

M&A Slower Than Some Had Anticipated

Cresco's latest news further suggests that larger-scale deals are happening in 2022. Still, several sources feel the year's M&A activity has been slower than expected.

Morgan Paxha, co-founder and managing director of Poseidon Asset Management said muted market activity isn't a surprise due to macro-level risks and a busy 2021. His firm forecasts that 2022 will see smaller deals financed with cash, seller's notes and minor equity issuance.

Still, a more substantial or higher frequency of deals isn't out of the picture.

"We believe larger events will resume as risk appetite returns as that will be more impactful to the acquirer's fundamentals," Paxhia said.

Sweet Leaf Madison Capital CFO Andrew J. Kaye said both opportunity and currency are in short supply for the near term. He cited an M&A "hangover" of sorts.

"Hangover from Croptober, dislocation from COVID, and competition from the legacy market due to high taxes have all contributed to sluggish sales," he said.

Down for the moment, Kaye does not see the current sales dip having a lasting impact on M&A deals.

George Mancheril, CEO and founder of Bespoke Financial cited macroeconomic concerns and geopolitical turmoil as primary factors in a slow 2022.

"This has obviously had an effect on our industry and led to less M&A transactions than may have initially been forecasted," said Mancheril.

Still, he notes that the Cresco-Columbia Care deal does indicate that significant activity will still occur.

Q1 Reports Will Play A Critical Role

Many in the market are readying themselves for M&A to tick up in the latter stages of 2022. In the meantime, John Kagia, chief knowledge officer for New Frontier Data said that eyes and ears remain glued to Q1 2022 sales revenue reports.

He reported that cannabis seasonality trends have shown sales declining between October and February in past years. Kagia added that high inflation rates, supply chain disruptions and rising consumer prices may have played possible roles in market activity.

"We know that cannabis is highly recession resilient, but facing tightening finances, consumer efforts at cost savings may negatively impact legal operator revenue over the coming months," Kagia said.

Photo created by rawpixel.com - www.freepik.com

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
CannabisM&ANewsMarketsInterviewAcquisitionsMergersNew Frontier DataPoseidon Asset Management
CGC Logo
CGCCanopy Growth Corp
$1.160.87%
Overview
CRLBF Logo
CRLBFCresco Labs Inc
$0.9703-3.93%
CGC Logo
CGCCanopy Growth Corp
$1.160.87%
Overview
CRLBF Logo
CRLBFCresco Labs Inc
$0.9703-3.93%
Beat the Market With Our Free Pre-Market Newsletter
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
Comments
Loading...